Astrazeneca

FromAstraZeneca ([email protected])
Subject (50)Eneboparatide Phase III trial met primary endpoint
Preheader (47)͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Typography
Arial
Colors
Text Analysis
Body Words242
Subject Words7
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px734 px
X-Spam Score0.7
Preheader OptimizedNo
Timing
Day of WeekTuesday
TimeEvening

Eneboparatide Phase III trial met primary endpoint

͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏ ͏
Eneboparatide Phase III trial met primary endpoint